حول GRIFOLS Egypt
Grifols' origin lies in the laboratory founded in 1940 in Barcelona by Dr Josep A. Grífols Roig, a hematologist and scientist (although its origin dates back to the Instituto Central de Análisis Clínicos, a company founded in 1909 by Josep Antonio Grífols Roig, which will be a pioneer in Spain in clinical analysis and in the introduction of blood conservation and transfusion techniques).[5] His son, Dr Josep A. Grifols Lucas was the first researcher to publish the plasmapheresis procedure in 1952.[6] The company introduced its liquid IVIG product into the European market in the mid-1990s. Probitas Pharma, S.A. was incorporated with high limited liability under Spanish law on 22 June 1987; on 27 June 2005 the company changed its name to Grifols, S.A.[7][self-published source] In 2003 the company acquired certain assets of the Los Angeles-based Alpha Therapeutic (US subsidiary of Mitsubishi Pharma) as the basis of its American expansion.[8] On May 17, 2006, Grifols securities were listed on Spain's Mercado Continuo.[9] In 2009, CSL Limited attempted to takeover Talecris Biotherapeutics (the former plasma business of Bayer HealthCare LLC, Biological Products Division)[10] for $3,1 billion but was stopped by the Federal Trade Commission.[11] On June 1, 2011, a year after announcing the $4 billion deal, Grifols completed a takeover of Talecris Biotherapeutics, headquartered in Research Triangle Park in North Carolina, with over 2000 employees.[12] Grifols acquired the blood transfusion diagnostics unit from Novartis in 2013 as a "platform for global expansion".[3] This unit is based in Emeryville, California and was a part of Chiron acquired by Novartis in 2006.[3] In 2015, the company acquired a 45% stake in Alkahest as part of planned co-development of "plasma-based products for the treatment of cognitive decline in aging and disorders of the CNS, including Alzheimer's."[13] In 2020 Grifols acquired the remaining stock of Alkahest “bringing its ownership of Alkahest to 100%”.[14] In December 2016, Grifols acquired Hologics interest in their existing joint blood screening unit for $1.85 billion
